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EDITORIAL
A Nordic initiative for a more personal and accurate diagnostic pathway for
prostate cancer
Prostate cancer (PCa) is currently a textbook example of
over-diagnosis and over-treatment. Nevertheless, it is the
most commonly diagnosed cancer and the second lead-
ing cause of cancer-related death in men in the Nordic
countries (Figure 1) [1]. Due to demographic changes,
the incidence of PCa is expected to rise by up to 40% in
the next 20 years. Consequently, PCa is a challenge for
the health care system and health economy.
According to Beauchamp and Childress [2], there are
four global ethical principles in medicine: (A) beneficence,
(B) non-maleficence, (C) justice and (D) respect of (the
patient’s) autonomy. From our perspective, the current
diagnostic pathway for PCa challenges all of these princi-
ples. First, there is no beneficence for patients in over-
diagnosis and over-treatment, but rather a risk of harm.
Second, resources in the health care system are not uti-
lized justly. Third, the diagnostic procedure may lack the
patient’s consent or, where consent is obtained, it may
be uninformed. Consequently, the challenges in dealing
with PCa are also ethical.
Under- and over-diagnosis depend on the sensitivity
and specificity of the diagnostic tests used. If the sensitiv-
ity of a test increases, the specificity usually reduces, and
vice versa. Consequently, new tests with higher accuracy
are needed to improve the diagnosis of PCa. Henrik
Gr€onberg and his team in Stockholm have been working
on a new approach for PCa diagnosis since 2010. Their
efforts have resulted in a Nordic research collaboration
(NorDCaP) focusing on improving several of the steps in
the diagnostic pathway for PCa.
The first and crucial step is to decide whether or not
to test. A Norwegian study indicates that GPs in Norway
are experiencing strong pressure from patients to con-
duct examinations to detect illness [3]. While urological
symptoms are common [4], their association to PCa is
low [5]. The main problem with the test currently in use,
prostate-spesific antigen (PSA), is low specificity at a level
of acceptable sensitivity. This is why Nordic guidelines
recommend against PSA-based population screening, as
the problems with over-diagnosis and over-treatment are
considered to outweigh the possible benefits.
Nevertheless, opportunistic PSA testing is still widespread
in the Nordic countries.
Various guidelines state that patients must be well
informed before consenting to PCa testing. To improve
this process, Capio S:t G€oran Hospital in Stockholm has
developed and implemented a strategy with mandatory
information provision to ensure patients are well-
informed before making the decision [6].
The next step is selecting patients for further work-up.
To improve this, Gr€onberg et al. have developed a new
blood-based test called Stockholm3. In it, an algorithm
combines the results of PSA, four other plasma proteins,
more than 100 genetic markers and some clinical data to
make a PCa risk assessment. It results in a better selec-
tion of men for further work-up than PSA alone [7]. The
Stockholm3 test is more expensive than PSA and should
be evaluated based on clinical outcome and health eco-
nomics. Experiences from implementing this test in regu-
lar clinical practice in the Stavanger region of Norway are
described in a research article in this issue of SJPHC [8].
When men are referred for further diagnostic work-up
due to suspected PCa, a prostate gland biopsy is crucial
for diagnosis but traditionally only a small proportion of
biopsied men are diagnosed with clinically significant
PCa; most diagnoses are for clinically non-significant PCa
or no cancer at all [9]. Unfortunately, a biopsy results in
sepsis among 2–5% of the cases. Consequently, better
procedures are needed for selecting biopsied patients.
Besides a better blood test, a prostate MRI may be help-
ful, but there is still debate as to whether the accuracy is
sufficient that a biopsy can be avoided in cases of nega-
tive MRI [10]. Ongoing NorDCaP projects are working on
developing an AI-based tool to assist radiologists in MRI
evaluation. The ambition is that the tool can improve
MRI interpretation to the extent that biopsies can be
avoided in men with a negative MRI. The research will at
least clarify whether biopsies can be avoided with a
negative MRI if the Stockholm3 risk score is below a cer-
tain cut-off.
The next step after a biopsy is a pathological examin-
ation of the tissue sample. New technologies, including
sample digitization and AI, are being applied to develop
a pathological tool that will provide a more reliable diag-
nosis of prostate biopsies [11]. With funding from
NordForsk, NorDCaP aims to develop and implement a
more accurate and personalized diagnostic pathway for
PCa, better to deal with the clinical, health economic and
ethical challenges that PCa represents today. Based on
this knowledge, the consortium will develop infrastruc-
ture for a pan-Nordic quality register for PCa diagnosis.
The purpose of the register is to help health care regions
evaluate their own practices regarding PCa diagnosis,
and to provide support for clinical implementation of
best practices in the Nordic countries.
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It is too early to draw conclusions, but we believe that
even moderate improvements of each step in the diag-
nostic pathway will provide a valuable and significant
improvement in the diagnosis of PCa. Ultimately, this
novel and more personalized diagnostic approach should
considerably reduce the number of prostate biopsies and
the over-diagnosis of indolent PCa, while still ensuring
early detection of clinically significant PCa when it is
still curable.
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Figure 1. Incidence and mortality rates for prostate cancer
per 100,000 inhabitants in the Nordic countries from 1960 to
2016 according to NORDCAN [1].
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